Lodmell D L, Ewalt L C
Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, 903 South Forth Street, Hamilton, USA.
Vaccine. 2000 May 8;18(22):2394-8. doi: 10.1016/s0264-410x(00)00005-0.
Long-term levels of neutralizing antibody were evaluated in mice after a single immunization with experimental DNA or recombinant vaccinia virus (RVV) vaccines encoding the rabies virus glycoprotein (G), or the commercially available inactivated virus human diploid cell vaccine (HDCV). Anamnestic antibody titers were also evaluated after two booster immunizations with vaccines that were identical to or different from the priming vaccine. Five hundred and forty days (1.5 year) after a single immunization with any of the three vaccines, neutralizing antibody titers remained greater than the minimal acceptable human level of antibody titer (0.5 International Units (IU)/ml). In addition, either an HDCV or DNA booster elicited early and elevated anamnestic antibody responses in mice that had been primed with any of the three vaccines. In contrast, RVV boosters failed to elevate titers in mice that had been previously primed with RVV, and elicited slowly rising titers in mice that had been primed with either DNA or HDCV. Thus, a single vaccination with any of the three different vaccines elicited long-term levels of neutralizing antibody that exceeded 0.5 IU/ml. In contrast, different prime-booster vaccine combinations elicited anamnestic neutralizing antibody responses that increased quickly, increased slowly or failed to increase.
用编码狂犬病病毒糖蛋白（G）的实验性DNA或重组痘苗病毒（RVV）疫苗，或市售的灭活病毒人二倍体细胞疫苗（HDCV）对小鼠进行单次免疫后，评估其长期中和抗体水平。在用与初次免疫疫苗相同或不同的疫苗进行两次加强免疫后，也评估了回忆性抗体滴度。用三种疫苗中的任何一种进行单次免疫540天（1.5年）后，中和抗体滴度仍高于可接受的最低人类抗体滴度水平（0.5国际单位（IU）/毫升）。此外，HDCV或DNA加强免疫在已用三种疫苗中的任何一种进行初次免疫的小鼠中引发了早期且升高的回忆性抗体反应。相比之下，RVV加强免疫未能提高先前用RVV进行初次免疫的小鼠的滴度，并且在已用DNA或HDCV进行初次免疫的小鼠中引发了缓慢上升的滴度。因此，用三种不同疫苗中的任何一种进行单次疫苗接种都会引发超过0.5 IU/ml的长期中和抗体水平。相比之下，不同的初次免疫-加强免疫疫苗组合引发的回忆性中和抗体反应迅速增加、缓慢增加或未能增加。
